Three Things That Pharma Executives Must Do to Keep Pace With the Healthcare Evolution

Posted by Ian Wilcox on Thu, Dec 20, 2018

Just over a week ago, CVS Health announced that it had closed the deal on the merger heard ’round the world: the highly anticipated acquisition of insurance giant Aetna. CVS Health President and Chief Executive Officer Larry Merlo said in a statement that the merger will “transform the consumer health experience and build healthier communities through a new, innovative healthcare model that is local, easier to use, less expensive and puts consumers at the center of their care.”


>
Read More

The Humira Question: Will the Adalimumab Biosimilars Live Up to the Hype?

Posted by Prateek Yadav on Fri, Dec 07, 2018

Prateek Yadav co-wrote this blog post with Christina Corridon, Tucker Herbert, Didier Chicheportiche and Gustavo Poblete.

The biosimilars market in Europe continues to generate buzz as it captures considerable market share from major blockbuster-branded biologics. Most recently, Celltrion's Truxima, a biosimilar of Roche's MabThera (rituximab), captured 32% market share in 18 European countries. Regulatory agencies have also welcomed biosimilars for the promise of the potential cost savings that they bring. Earlier, the U.K.’s National Health Service reported that switching patients from branded drugs to biosimilars and generics led to a savings of £324 million last year.


>
Read More

New ZS Research on Forecasting in an Evolving Landscape

Posted by Ram Ramakrishnan on Mon, Jul 09, 2018

This post is the second in a four-part series on how pharmaceutical companies can elevate their forecasting operations.

The pharmaceutical industry is facing an increasingly challenging environment with looming biosimilar launches, tighter access and pricing controls, and saturation within primary care markets. Forecasting as a functional area is affected by these changes, given the range of decisions that forecasts inform.


>
Read More